Hutchison China Meditech Ltd (HCM)

 

Latest News

Why Shell was kicked out of this top-performing portfolio

This portfolio has returned 275% since 2010; David Brenchley finds out which potential "money-making machine" has mo...

Chi-Med present pre-clinical data at AACR

Hutchison China MediTech presented pre-clinical data for fruquintinib and sulfatinib at the American Association for Ca...

Pre-clinical Data Presented at AACR

RNS Number: 8957B Hutchison China Meditech Limited 07 April 2017 Press Release Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017 London: Friday, April 7, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) presented pre-clinical data for fruquintin...

Total Voting Rights

RNS Number: 1321B Hutchison China Meditech Limited 31 March 2017 Total Voting Rights London: Friday , March 31, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the issued share capital of Chi-Med consisted of 60,715,323 ordinary shares of US$1.00 each, wi...

All News

DateHeadlineSource
13-04-17Why Shell was kicked out of this top-performing portfolioInteractive Investor
07-04-17Chi-Med present pre-clinical data at AACRStockMarketWire
07-04-17Pre-clinical Data Presented at AACRRNS
31-03-17Total Voting RightsRNS
29-03-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
29-03-17Vesting of LTIP awardsRNS
28-03-17Grant of Share Options under Share Option SchemeRNS
27-03-172016 Annual Report and Notice of AGMRNS
24-03-17Chi-Med chief scientific officer joins board StockMarketWire
24-03-17Appointment of DirectorRNS
21-03-17Chi-Med to host R&D BriefingsRNS
20-03-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
20-03-17Directors' Share DealingRNS
16-03-17Grant of Awards under Long Term Incentive PlanRNS
13-03-17Hutchison China MediTech shares tipped to hit record highInteractive Investor
13-03-17Higher commodity prices boost FTSE as May considers triggering Article 50StockMarketWire
13-03-17Record revenues and net income at Chi-Med StockMarketWire
13-03-17Publication of Form 20-FRNS
13-03-17Final ResultsRNS
10-03-17Chi-Med presents pre-clinical data at ENETSStockMarketWire
10-03-17Sulfatinib Phase Ib/II Results Presented at ENETSRNS
10-03-17Sulfatinib Phase Ib/II Results Presented at ENETSRNS
03-03-17Chi-Med reveals positive results from cancer drug trial StockMarketWire
03-03-17Positive Fruquintinib Pivotal Phase III ResultsRNS
28-02-17Board changes at HCMStockMarketWire
28-02-17Change of DirectorsRNS
20-02-17Chi-Med starts Savolitinib PSC trial in ChinaStockMarketWire
20-02-17Start of Phase II Savolitinib PSC trial in ChinaRNS
20-02-17Start of Phase II Savolitinib PSC trial in ChinaRNS
14-02-17Chi-Med and AZ to present savolitinib results at symposiumStockMarketWire
14-02-17Initiates Phase I of Novel FGFR Inhibitor HMPL-453RNS
14-02-17Savolitinib PRCC Results Presentation at ASCO GURNS
06-02-17Chi-Med to Announce 2016 Final ResultsRNS
01-02-17Change of DirectorsRNS
20-01-17Why resurgent AIM could keep rising Interactive Investor
16-01-17Change of DirectorsRNS
16-01-17Change of DirectorsRNS
16-01-17Chi-Med launches cancer studies in China StockMarketWire
16-01-17Fruquintinib Phase I/II Clinical Data at ASCO GIRNS
16-01-17Sulfatinib Phase II Study in 2nd Line BTC in ChinaRNS

RSS feeds

  • Editorial news feed for LSE:HCM Editorial
  • Regulatory news feed for LSE:HCM Regulatory